EP 2557923 A4 20131023 - TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

Title (en)

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

Title (de)

BEHANDLUNG VON KREBSERKRANKUNGEN MIT K-RAS-MUTATIONEN

Title (fr)

TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS

Publication

EP 2557923 A4 20131023 (EN)

Application

EP 11769663 A 20110415

Priority

US 32491210 P 20100416
US 2011032683 W 20110415

Abstract (en)

[origin: WO2011130628A1] The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

IPC 8 full level

A61K 31/167 (2006.01); A61K 31/16 (2006.01); A61K 31/19 (2006.01); A61K 31/343 (2006.01); A61K 31/38 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5355 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP)

A61K 31/16 (2013.01); A61K 31/167 (2013.01); A61K 31/19 (2013.01); A61K 31/343 (2013.01); A61K 31/38 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/5355 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2017.12); A61P 43/00 (2017.12)

C-Set (source: EP)

Citation (search report)

[XI] WO 2009155659 A1 20091230 - UNIV QUEENSLAND [AU], et al
[XI] WO 2008076447 A2 20080626 - ORDWAY RES INST [US], et al
[XI] WO 2006097449 A1 20060921 - MENARINI INT OPERATIONS LU SA [LU], et al
[XI] WO 2009129335 A2 20091022 - PHARMACYCLICS INC [US], et al
[XI] DENLINGER ET AL: "Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 130, no. 5, 1 November 2005 (2005-11-01), pages 1422 - 1429, XP005127283, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2005.06.051
[XI] WANG QINGDING ET AL: "Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1940 - 1947, XP055079069, ISSN: 1078-0432
[XI] M A LEA ET AL: "Induction of Differentiation of Colon Cancer Cells by Combined Inhibition of Kinases and Histone Deacetylase", ANTICANCER RESEARCH, vol. 27, 1 January 2007 (2007-01-01), pages 741 - 748, XP055079030
[XI] YU X-D ET AL: "Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 13, no. 2, 1 March 2007 (2007-03-01), pages 105 - 113, XP008111377, ISSN: 1528-9117
[XI] REDDY G K: "EARLY CLINICAL DATA AND POTENTIAL CLINICAL UTILITY OF NOVEL HISTONE DEACETYLASE INHIBITORS IN PROSTATE CANCER", CLINICAL PROSTATE CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 4, no. 2, 1 January 2005 (2005-01-01), pages 83 - 85, XP009079218, ISSN: 1540-0352
[AP] CHIA-WEI CHOU ET AL: "HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells", PLOS ONE, vol. 6, no. 3, 25 March 2011 (2011-03-25), pages e18087, XP055078579, DOI: 10.1371/journal.pone.0018087
[A] E LOPEZ-CRAPEZ ET AL: "Rapid and large-scale method to detect K-ras gene mutations in tumor samples", CLINICAL CHEMISTRY, 1 January 1997 (1997-01-01), pages 936 - 942, XP055078570, Retrieved from the Internet <URL:http://www.clinchem.org/content/43/6/936.full.pdf+html> [retrieved on 20130910]
[A] G. J. RIELY ET AL: "KRAS Mutations in Non-Small Cell Lung Cancer", PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY, vol. 6, no. 2, 15 April 2009 (2009-04-15), pages 201 - 205, XP055024772, ISSN: 1546-3222, DOI: 10.1513/pats.200809-107LC
[A] PERGOLIZZI ROBERT G ET AL: "Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas", CANCER INVESTIGATION, vol. 11, no. 1, 1993, pages 25 - 32, XP008164834, ISSN: 0735-7907
[A] FRANKLIN WILBUR A ET AL: "KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cance", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 12, no. 1, 1 January 2010 (2010-01-01), pages 43 - 50, XP009168344, ISSN: 1525-1578
[A] JEET GANDHI ET AL: "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 2, 24 February 2009 (2009-02-24), pages E4576 - 1, XP002677508, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004576
[A] KRYPUY MICHAEL ET AL: "High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 21 December 2006 (2006-12-21), pages 295, XP021023081, ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-295
[AP] N SUNAGA ET AL: "Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 10, 1 January 2011 (2011-01-01), pages 336 - 346, XP055079048
See references of WO 2011130628A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2011130628 A1 20111020; AU 2011239537 A1 20121115; CA 2795952 A1 20111020; CN 102970868 A 20130313; EP 2557923 A1 20130220; EP 2557923 A4 20131023; JP 2013525308 A 20130620

DOCDB simple family (application)

US 2011032683 W 20110415; AU 2011239537 A 20110415; CA 2795952 A 20110415; CN 201180029056 A 20110415; EP 11769663 A 20110415; JP 2013505177 A 20110415